CN117121949A - 一种重建及强化人体免疫功能的成人配方奶粉 - Google Patents
一种重建及强化人体免疫功能的成人配方奶粉 Download PDFInfo
- Publication number
- CN117121949A CN117121949A CN202311233371.XA CN202311233371A CN117121949A CN 117121949 A CN117121949 A CN 117121949A CN 202311233371 A CN202311233371 A CN 202311233371A CN 117121949 A CN117121949 A CN 117121949A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- milk powder
- milk
- zinc
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 78
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 59
- 230000036039 immunity Effects 0.000 title claims abstract description 35
- 238000005728 strengthening Methods 0.000 title abstract description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 66
- 239000002366 mineral element Substances 0.000 claims abstract description 35
- 229910052742 iron Inorganic materials 0.000 claims abstract description 34
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000016804 zinc Nutrition 0.000 claims abstract description 33
- 239000011701 zinc Substances 0.000 claims abstract description 33
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 33
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 32
- 229940088594 vitamin Drugs 0.000 claims abstract description 29
- 229930003231 vitamin Natural products 0.000 claims abstract description 29
- 235000013343 vitamin Nutrition 0.000 claims abstract description 29
- 239000011782 vitamin Substances 0.000 claims abstract description 29
- 230000002708 enhancing effect Effects 0.000 claims abstract description 27
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 23
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 23
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 23
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000016709 nutrition Nutrition 0.000 claims abstract description 16
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 15
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 15
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 15
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 15
- 239000011719 vitamin A Substances 0.000 claims abstract description 15
- 229940045997 vitamin a Drugs 0.000 claims abstract description 15
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 14
- 230000035764 nutrition Effects 0.000 claims abstract description 14
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 13
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 13
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 13
- 239000011718 vitamin C Substances 0.000 claims abstract description 13
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 13
- 239000011710 vitamin D Substances 0.000 claims abstract description 13
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 13
- 229940046008 vitamin d Drugs 0.000 claims abstract description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 13
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 12
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 11
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 11
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 11
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 11
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 11
- 235000018102 proteins Nutrition 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002773 nucleotide Substances 0.000 claims abstract description 10
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 10
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 10
- 229940046009 vitamin E Drugs 0.000 claims abstract description 10
- 239000011709 vitamin E Substances 0.000 claims abstract description 10
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 9
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 9
- 235000015097 nutrients Nutrition 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 7
- 229960001231 choline Drugs 0.000 claims abstract description 7
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960003080 taurine Drugs 0.000 claims abstract description 7
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 claims abstract description 6
- 239000011669 selenium Substances 0.000 claims abstract description 6
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 6
- 235000011649 selenium Nutrition 0.000 claims abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011575 calcium Substances 0.000 claims abstract description 5
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 4
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000011777 magnesium Substances 0.000 claims abstract description 4
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- 235000013336 milk Nutrition 0.000 claims description 49
- 239000008267 milk Substances 0.000 claims description 49
- 210000004080 milk Anatomy 0.000 claims description 49
- 230000036737 immune function Effects 0.000 claims description 38
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 20
- 235000020185 raw untreated milk Nutrition 0.000 claims description 19
- 230000006870 function Effects 0.000 claims description 18
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 18
- 102000007544 Whey Proteins Human genes 0.000 claims description 15
- 108010046377 Whey Proteins Proteins 0.000 claims description 15
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 15
- 229940011671 vitamin b6 Drugs 0.000 claims description 15
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- -1 vitamin compound Chemical class 0.000 claims description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 235000019197 fats Nutrition 0.000 claims description 12
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 12
- 235000019158 vitamin B6 Nutrition 0.000 claims description 12
- 239000011726 vitamin B6 Substances 0.000 claims description 12
- 235000021119 whey protein Nutrition 0.000 claims description 10
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 239000002131 composite material Substances 0.000 claims description 7
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 6
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims description 6
- 235000013861 fat-free Nutrition 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 235000010755 mineral Nutrition 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 229920000157 polyfructose Polymers 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 239000005862 Whey Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229940091258 selenium supplement Drugs 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 229960002477 riboflavin Drugs 0.000 claims description 4
- 239000002151 riboflavin Substances 0.000 claims description 4
- 235000019192 riboflavin Nutrition 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 3
- 239000011665 D-biotin Substances 0.000 claims description 3
- 235000000638 D-biotin Nutrition 0.000 claims description 3
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 3
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 3
- 239000002211 L-ascorbic acid Substances 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 230000008952 bacterial invasion Effects 0.000 claims description 3
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 3
- 230000007969 cellular immunity Effects 0.000 claims description 3
- 229960002104 cyanocobalamin Drugs 0.000 claims description 3
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 3
- 239000011666 cyanocobalamin Substances 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 3
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 claims description 3
- 239000011790 ferrous sulphate Substances 0.000 claims description 3
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 230000003871 intestinal function Effects 0.000 claims description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- 230000002147 killing effect Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229940099596 manganese sulfate Drugs 0.000 claims description 3
- 239000011702 manganese sulphate Substances 0.000 claims description 3
- 235000007079 manganese sulphate Nutrition 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000000242 pagocytic effect Effects 0.000 claims description 3
- 230000035790 physiological processes and functions Effects 0.000 claims description 3
- 235000007715 potassium iodide Nutrition 0.000 claims description 3
- 235000020610 powder formula Nutrition 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 229960000342 retinol acetate Drugs 0.000 claims description 3
- 235000019173 retinyl acetate Nutrition 0.000 claims description 3
- 239000011770 retinyl acetate Substances 0.000 claims description 3
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 3
- 229960005055 sodium ascorbate Drugs 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 235000011083 sodium citrates Nutrition 0.000 claims description 3
- 239000011781 sodium selenite Substances 0.000 claims description 3
- 229960001471 sodium selenite Drugs 0.000 claims description 3
- 235000015921 sodium selenite Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 3
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 235000019871 vegetable fat Nutrition 0.000 claims description 3
- 235000019156 vitamin B Nutrition 0.000 claims description 3
- 239000011720 vitamin B Substances 0.000 claims description 3
- 235000008939 whole milk Nutrition 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 238000006471 dimerization reaction Methods 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 235000019175 phylloquinone Nutrition 0.000 claims 1
- 239000011772 phylloquinone Substances 0.000 claims 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims 1
- 229960001898 phytomenadione Drugs 0.000 claims 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 abstract description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 7
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 235000014121 butter Nutrition 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000357408 Ophiocordyceps sobolifera Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910001431 copper ion Inorganic materials 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940062827 2'-fucosyllactose Drugs 0.000 description 1
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 description 1
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- ODDPRQJTYDIWJU-UHFFFAOYSA-N 3'-beta-D-galactopyranosyl-lactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C1O ODDPRQJTYDIWJU-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- ODDPRQJTYDIWJU-OAUIKNEUSA-N beta-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O ODDPRQJTYDIWJU-OAUIKNEUSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000020191 long-life milk Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 108010071421 milk fat globule Proteins 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 235000020122 reconstituted milk Nutrition 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/004—Artificial life, i.e. computing arrangements simulating life
- G06N3/006—Artificial life, i.e. computing arrangements simulating life based on simulated virtual individual or collective life forms, e.g. social simulations or particle swarm optimisation [PSO]
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Theoretical Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Computing Systems (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Artificial Intelligence (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Computational Linguistics (AREA)
- Data Mining & Analysis (AREA)
- Evolutionary Computation (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Mathematical Physics (AREA)
- Software Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种重建及强化人体免疫功能的成人配方奶粉,涉及配方奶粉领域,解决的问题是重建及强化人体免疫功能,成人配方奶粉包括以下配方:基础营养元素、矿物质元素、维生素元素、强化营养成分和强化免疫成分,基础营养元素包括蛋白质、脂肪和碳水化合物,矿物质元素包括钠、镁、铁、锌、锰、钙和硒,维生素元素包括维生素A、维生素D、维生素E、维生素B6和维生素C,强化营养成分包括DHA、ARA、牛磺酸、核苷酸、胆碱和益生元,强化免疫成分包括表皮生长因子EGF、酵母β‑葡聚糖和乳铁蛋白。本发明通过粒子群算法计算锌和铁的最优添加比例;通过添加强化免疫成分重建及人体免疫功能,适用于大众人群。
Description
技术领域
本发明涉及配方奶粉领域,且更具体地涉及一种重建及强化人体免疫功能的成人配方奶粉。
背景技术
人体免疫功能失调或免疫系统不健全时,身体极易招致细菌、病毒、真菌等感染,易导致感冒反复发作、扁桃体炎反复发作、哮喘反复发作、支气管炎反复发作、肺炎反复发作和腹泻反复发作,还易诱发重大疾病,当免疫力低下时应多补充一些含锌、硒和蛋白质的食物,通过富含锌、硒、蛋白质及强化免疫元素的成人配方奶粉能够重建及强化人体免疫功能。
专利号CN202210235306.X公开一种重建及强化人体免疫功能的成人配方奶粉,通过每天饮用成人配方奶粉能够显著增强人体免疫力,重建及强化人体免疫功能的成人配方奶粉包括奶粉基础组分和免疫因子;其中,所述免疫因子为蝉花子实体,但是,蝉花子实体在孕妇、哺乳期妇女、食用菌过敏者人群中的食用安全性资料不足,从风险预防原则考虑,上述人群不宜食用,因此需要一种重建及强化人体免疫功能的成人配方奶粉,能够重建及强化大众人群人体免疫功能。
发明内容
针对现有技术的不足,本发明公开了一种重建及强化人体免疫功能的成人配方奶粉,能够重建及强化大众人群人体免疫功能;通过粒子群算法计算锌和铁的最优添加比例,实现人体吸收最大化;通过添加维生素B6、核苷酸、益生元、酵母β-葡聚糖和乳铁蛋白强化机体免疫功能;通过添加表皮生长因子重建人体免疫功能。
作为本发明进一步的技术方案,一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:包括以下配方:
基础营养元素,用于人体基础营养供能,所述基础营养元素包括蛋白质、脂肪和碳水化合物,所述蛋白质含量占原料成分的百分比为29%-35%,所述脂肪含量占原料成分的百分比为20%-23%,所述碳水化合物含量占原料成分的百分比为45%-48%,所述基础营养元素为人体基础营养总供能2002kJ/100g-2020kJ/100g;
矿物质元素,用于提高人体机能,所述矿物质元素包括钠、镁、铁、锌、锰、钙和硒,所述成人配方奶粉每100g中矿物质元素含量分别为钠300-330mg、镁40-46mg、铁6.0-7.9mg、锌5.5-6.5mg、锰230-240μg、钙850-1000mg和硒18.0-21.0μg,所述矿物质元素锌和铁通过参与人体酶合成实现机体免疫功能调节;
维生素元素,用于维持人体生理机能,所述维生素元素包括维生素A、维生素D、维生素E、维生素B6和维生素C,所述成人配方奶粉每100g中维生素元素含量分别为维生素A450-550μg、维生素D7.5-7.9μg、维生素E10.0-12.5mg、维生素B6500-1200μg和维生素C30-63mg,所述维生素A、维生素D和维生素B6调节通过增强细胞吞噬能力和杀伤能力调节机体免疫功能,所述维生素B6的添加量为600μg/100g,所述维生素C的添加量为40mg/100g;
强化营养成分,用于强化人体机能,所述强化营养成分包括二十二碳六烯酸DHA、二十碳四烯酸ARA、牛磺酸、核苷酸、胆碱和益生元,所述益生元包括低聚异麦芽糖和多聚果糖,所述强化营养成分占原料成分的百分比为二十二碳六烯酸0.20-0.25%、二十碳四烯酸0.3-0.5%、牛磺酸0.03-0.04%、核苷酸0.04-0.05%、胆碱0.01-0.15%、低聚半乳糖0.2-0.9%和多聚果糖3.6-4.2%,所述核苷酸和益生元通过改善肠道功能实现机体细胞免疫力增强;
强化免疫成分,用于重建及强化人体免疫功能,所述强化免疫成分包括表皮生长因子EGF、酵母β-葡聚糖和乳铁蛋白,表皮生长因子EGF含量占原料成分的百分比为0.008%-0.010%,酵母β-葡聚糖含量占原料成分的百分比为0.03%-0.10%,乳铁蛋白含量占原料成分的百分比为0.05%-0.08%,所述表皮生长因子通过修复呼吸道和消化道的上皮粘膜细胞防止细菌侵入,以提高人体机体免疫力。
作为本发明进一步的技术方案,所述成人配方奶粉的制作过程包括以下步骤:
步骤一、采集新鲜生牛奶进行检验、过滤、净化和标准化处理,并将鲜奶与奶粉配方微量元素液体混合形成原料乳,所述原料乳中脂肪与无脂干物质的比例等于生产奶粉中脂肪与无脂干物质的比例;
步骤二、采用高温短时间或超高温瞬时杀菌方法对原料乳进行杀菌处理;
步骤三、加入蔗糖,所述成人配方奶粉的含糖量小于20%;
步骤四、通过真空浓缩去除原料乳中75%-80%的水分子,以提高奶粉的保藏性;
步骤五、通过高压或高速离心力实现原料乳喷雾干燥形成浓缩乳,所述浓缩乳通过雾化器向干燥室喷雾与热空气接触实现水分蒸发,以形成颗粒状奶粉。
作为本发明进一步的技术方案,所述矿物质元素通过粒子群算法计算出锌和铁的最优摄入比例,以实现人体吸收最大化,所述矿物质元素锌和铁比例样本的集合为D,将所述集合D分为j个类别的集合为D=(D1,D2,...,Di,...,Dj),矿物质元素锌和铁比例样本类别Di需要经验熵的输出函数公式为:
在公式(1)中,pi为任意矿物质元素锌和铁的比例样本属于类别Di的概率,H(Di)为给定样本类别Di需要的经验熵;
不同矿物质元素锌和铁比例的免疫性能效果集合为A=[a1,a2,...,av},采用免疫性能效果将矿物质元素锌和铁比例样本的集合D分为(D1,D2,...,DV),将A划分为子集的经验熵输出函数公式为:
在公式(2)中,E(A)为将A划分为子集的经验熵,Sij为子集Dj的免疫性能效果类别样本,s为矿物质元素锌和铁比例的样本数,H(Di)为给定样本类别Di需要的经验熵,E(A)值与免疫性能效果成反比。
作为本发明进一步的技术方案,所述矿物质元素的化合物包括柠檬酸钠、硫酸镁、硫酸亚铁、硫酸锌、硫酸锰、碘化钾、碳酸钙和亚硒酸钠。
作为本发明进一步的技术方案,所述维生素元素化合物包括脂溶性维生素化合物和水溶性维生素化合物。
作为本发明进一步的技术方案,所述脂溶性维生素包括醋酸维生素A、维生素D、维生素E、dl-α-醋酸生育酚和植物甲萘醌;所述水溶性维生素包括维生素B6、维生素C、L-抗坏血酸、L-抗坏血酸钠、盐酸硫胺素、核黄素、盐酸吡哆醇、氰钴胺、D-泛酸钙和D-生物素。
作为本发明进一步的技术方案,所述表皮因子EGF通过小分子多肽与应答细胞表面的受体结合实现受体二聚化和细胞质磷酸化,所述受体与不同序列的蛋白结合实现信号传导,以增强机体免疫功能。
作为本发明进一步的技术方案,所述成人配方奶粉的组分重量份数包括植物脂肪粉25-35份、乳粉30-42.5份、乳清粉21.5-30份、糖类固体糖浆1.096-8.93份、乳清蛋白粉2-4份、低聚糖1.5-2.5份、复合维生素0.15-0.2份、复合矿物质0.35-0.6份、强化营养素1-1.5份和免疫营养素0.8-1.0份。所述糖类为低聚异麦芽糖、低聚果糖、低聚半乳糖、木糖醇或赤藓糖醇。
作为本发明进一步的技术方案,所述成人配方奶粉采用的乳粉为全脂乳粉;所述成人配方奶粉采用的复合微生物包括乳双歧杆菌HN019、动物双歧杆菌Bb-12和鼠李糖乳杆菌,所述复合微生物含量大于1×106CFU/100g。
积极有益效果:
本发明公开了一种重建及强化人体免疫功能的成人配方奶粉,能够重建及强化大众人群人体免疫功能;通过粒子群算法计算锌和铁的最优添加比例,实现人体吸收最大化;通过添加维生素B6、核苷酸、益生元、酵母β-葡聚糖和乳铁蛋白强化机体免疫功能;通过添加表皮生长因子重建人体免疫功能。
附图说明
图1为本发明一种重建及强化人体免疫功能的成人配方奶粉组分重量份数示意图;
图2为本发明一种重建及强化人体免疫功能的成人配方奶粉基础营养元素的百分比含量示意图;
图3为本发明一种重建及强化人体免疫功能的成人配方奶粉矿物质元素含量示意图;
图4为本发明一种重建及强化人体免疫功能的成人配方奶粉维生素元素含量示意图;
图5为本发明一种重建及强化人体免疫功能的成人配方奶粉强化营养成分的百分比含量示意图;
图6为本发明一种重建及强化人体免疫功能的成人配方奶粉强化免疫成分的百分比含量示意图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:包括以下配方:
基础营养元素,用于人体基础营养供能,所述基础营养元素包括蛋白质、脂肪和碳水化合物,所述蛋白质含量占原料成分的百分比为29%-35%,所述脂肪含量占原料成分的百分比为20%-23%,所述碳水化合物含量占原料成分的百分比为45%-48%,所述基础营养元素为人体基础营养总供能2002kJ/100g-2020kJ/100g;
矿物质元素,用于提高人体机能,所述矿物质元素包括钠、镁、铁、锌、锰、钙和硒,所述成人配方奶粉每100g中矿物质元素含量分别为钠300-330mg、镁40-46mg、铁6.0-7.9mg、锌5.5-6.5mg、锰230-240μg、钙850-1000mg和硒18.0-21.0μg,所述矿物质元素锌和铁通过参与人体酶合成实现机体免疫功能调节;
维生素元素,用于维持人体生理机能,所述维生素元素包括维生素A、维生素D、维生素E、维生素B6和维生素C,所述成人配方奶粉每100g中维生素元素含量分别为维生素A450-550μg、维生素D7.5-7.9μg、维生素E10.0-12.5mg、维生素B6500-1200μg和维生素C30-63mg,所述维生素A、维生素D和维生素B6调节通过增强细胞吞噬能力和杀伤能力调节机体免疫功能,所述维生素B6的添加量为600μg/100g,所述维生素C的添加量为40mg/100g;
强化营养成分,用于强化人体机能,所述强化营养成分包括二十二碳六烯酸DHA、二十碳四烯酸ARA、牛磺酸、核苷酸、胆碱和益生元,所述益生元包括低聚异麦芽糖和多聚果糖,所述强化营养成分占原料成分的百分比为二十二碳六烯酸0.20-0.25%、二十碳四烯酸0.3-0.5%、牛磺酸0.03-0.04%、核苷酸0.04-0.05%、胆碱0.01-0.15%、低聚半乳糖0.2-0.9%和多聚果糖3.6-4.2%,所述核苷酸和益生元通过改善肠道功能实现机体细胞免疫力增强;
强化免疫成分,用于重建及强化人体免疫功能,所述强化免疫成分包括表皮生长因子EGF、酵母β-葡聚糖和乳铁蛋白,表皮生长因子EGF含量占原料成分的百分比为0.008%-0.010%,酵母β-葡聚糖含量占原料成分的百分比为0.03%-0.10%,乳铁蛋白含量占原料成分的百分比为0.05%-0.08%,所述表皮生长因子通过修复呼吸道和消化道的上皮粘膜细胞防止细菌侵入,以提高人体机体免疫力。
在上述实施例中,所述成人配方奶粉的制作过程包括以下步骤:
步骤一、采集新鲜生牛奶进行检验、过滤、净化和标准化处理,并将鲜奶与奶粉配方微量元素液体混合形成原料乳,所述原料乳中脂肪与无脂干物质的比例等于生产奶粉中脂肪与无脂干物质的比例;
步骤二、采用高温短时间或超高温瞬时杀菌方法对原料乳进行杀菌处理;
步骤三、加入蔗糖,所述成人配方奶粉的含糖量小于20%;
步骤四、通过真空浓缩去除原料乳中75%-80%的水分子,以提高奶粉的保藏性;
步骤五、通过高压或高速离心力实现原料乳喷雾干燥形成浓缩乳,所述浓缩乳通过雾化器向干燥室喷雾与热空气接触实现水分蒸发,以形成颗粒状奶粉。
在具体实施例中,原料乳必须新鲜,不能混有异常乳,比重应为1.028~1.032(20℃),酸度不超过20°T,含脂率不低于3.1%,乳固体不低于11.5%。杂菌数不超过20万个/毫升;若使用片式或管式杀菌器,通常采用的杀菌条件为80~85℃、保持30秒钟,或95℃,保持24秒钟。若用超高温瞬时杀菌装置,则为120~150℃,保持1~2秒钟;按国家规定标准,加糖乳粉中蔗糖含量应在20%以下;采用双效或三效真空蒸发器浓缩结束,浓缩乳应采用双联过滤器进行过滤;先将过滤的空气由鼓风机吸进,通过空气加热器加热至130~160℃后,送入喷雾干燥室。同时将过滤的浓缩乳由高压泵送至喷雾器或由奶泵送至离心喷雾转盘,喷成10~20微米的乳滴与热空气充分地接触,进行强烈的热交换和质交换,迅速地排除水分,在瞬间完成蒸发,干燥;随之沉降于干燥室底部,通过出粉机构不断地卸出,及时冷却,最后进行筛粉和包装。
奶粉的质量标准包括以下方面:
(1)感官指标:呈淡黄色的干燥粉末,不应有凝结的硬块及其它杂质,具有消毒牛乳的滋味和气味;
(2)理化指标:水分不高于3.00%,脂肪不低于26%,复原乳酸度不高于20°T,溶解度指数不低于1.5毫升,杂质度不高于16ppm,铅(以pb计)不高于0.5ppm,铜(以Cu计)不高于4ppm,汞(以Hg计)不高于0.03ppm,六六六不高于0.3ppm,DDT不高于0.2ppm;
(3)微生物指标:杂菌数不大于50000个/克,大肠菌群(近似值)不大于90个/100克,致病菌不得检出。
在上述实施例中,所述矿物质元素通过粒子群算法计算出锌和铁的最优摄入比例,以实现人体吸收最大化,所述矿物质元素锌和铁比例样本的集合为D,将所述集合D分为j个类别的集合为D=(D1,D2,...,Di,...,Dj),矿物质元素锌和铁比例样本类别Di需要经验熵的输出函数公式为:
在公式(1)中,pi为任意矿物质元素锌和铁的比例样本属于类别Di的概率,H(Di)为给定样本类别Di需要的经验熵;
不同矿物质元素锌和铁比例的免疫性能效果集合为A={a1,a2,...,av},采用免疫性能效果将矿物质元素锌和铁比例样本的集合D分为(D1,D2,...,DV),Sij为子集Dj的免疫性能效果类别样本,将A划分为子集的经验熵输出函数公式为:
在公式(2)中,E(A)为将A划分为子集的经验熵,Sij为子集Dj的免疫性能效果类别样本,s为矿物质元素锌和铁比例的样本数,H(Di)为给定样本类别Di需要的经验熵,E(A)值与免疫性能效果成反比。
上述工作实施过程中,可以将不同的组合成分转化为不同的信息参数,信息参数再转化为数学模型,以进行数据信息计算和运算,通过将微量成分转换为数据思维或模型,能够提高数据信息的计算能力。
在具体实施例中,免疫力和抗感染能力方面铁缺乏对免疫系统的影响包括抵抗病原微生物入侵的能力减弱;降低免疫细胞从静止到临战的反应速度;使抗氧化生化酶活性降低;抗体的生产停止或以很慢的速度进行;缺铁性贫血,细胞供氧不足。其结果是整天无精打采,疲劳而倦怠,比较容易被感染。离子间的相互作用的影响,钙离子和锌离子在吸收过程中有相互竟争的特性;铜离子与锌离子,他们的吸收也存在有竞争性拮抗作用;铁离子与锌离子在人体内也有相互抑制的作用;镉离子能干扰锌离子的吸收;锌离子可干扰铜离子的吸收;补铁离子可抑制锌离子的吸收;缺锌会影响铁离子的运转;影响矿物质的吸收有很多原因,矿物质摄入比例不合理会造成摄取不足现象,长期以往,就会影响到健康。
在上述实施例中,所述矿物质元素的化合物包括柠檬酸钠、硫酸镁、硫酸亚铁、硫酸锌、硫酸锰、碘化钾、碳酸钙和亚硒酸钠。
在上述实施例中,所述维生素元素化合物包括脂溶性维生素化合物和水溶性维生素化合物。
在上述实施例中,所述脂溶性维生素包括醋酸维生素A、维生素D、维生素E、dl-α-醋酸生育酚和植物甲萘醌;所述水溶性维生素包括维生素B6、维生素C、L-抗坏血酸、L-抗坏血酸钠、盐酸硫胺素、核黄素、盐酸吡哆醇、氰钴胺、D-泛酸钙和D-生物素。
在具体实施例中,免疫力强的人更不容易出现危重症,痊愈后出现后遗症的概率也相对小,而维护免疫力,促进康复,避免二次感染,都离不开维生素A的帮助,维生素A有促进上皮细胞的生长和分化的作用,对促进黏膜细胞增生,维持黏膜屏障的完整性有重要作用,而黏膜是免疫系统的第一道防线,保持体内维生素A充足,有助于加固这道防线;维生素D3补充剂调节了人体肠道菌群,对胃肠道疾病的改善,例如炎症性肠病或细菌感染有积极影响;由于维生素b6可以促进淋巴细胞分化成熟,促进机体产生抗体,从而维持人体的免疫力,此外,维生素b6在多种神经递质中起作用,可以帮助平衡脑细胞和为神经安定,另外,对于脂溢性皮炎的患者,服用维生素b6也可以改善症状。
在上述实施例中,所述表皮因子EGF通过小分子多肤与应答细胞表面的受体结合实现受体二聚化和细胞质磷酸化,所述受体与不同序列的蛋白结合实现信号传导,以增强机体免疫功能。
在具体实施例中,表皮生长因子EGF是一种低分子单链多肽,有53个氨基酸组成,具有耐热、耐酸性,EFG与受体结合后刺激靶细胞DNA合成和有丝分裂重建免疫屏障。
在上述实施例中,所述成人配方奶粉的组分重量份数包括植物脂肪粉25-35份、乳粉30-42.5份、乳清粉21.5-30份、糖类固体糖浆1.096-8.93份、乳清蛋白粉2-4份、低聚糖1.5-2.5份、复合维生素0.15-0.2份、复合矿物质0.35-0.6份、强化营养素1-1.5份和免疫营养素0.8-1.0份。所述糖类为低聚异麦芽糖、低聚果糖、低聚半乳糖、木糖醇或赤藓糖醇。
在具体实施例中,乳清粉以乳为原料,分离出来的含脂肪的部分,经加工制成的脂肪含量10.0%-80.0%的产品。无水奶油也叫无水黄油,以奶油或稀奶油为原料,经加工制成的脂肪含量不小于99.8%的产品,这两者都直接从乳汁中提取,是奶粉中天然乳脂的来源,即“天然OPO”,富含不饱和脂肪酸,容易吸收,可以减少钙皂,降低便秘几率。
脱盐乳清粉主要成分是乳清蛋白和乳糖,它可以通过脱去矿物质作用来增加奶粉中的乳糖含量、乳清蛋白含量,降低奶粉中矿物质含量,从而降低肾脏的代谢负担。乳脂浓缩乳清蛋白/粉、浓缩乳清蛋白/粉:牛奶中除去水,乳固体中的蛋白质后,剩余的就是乳清蛋白,乳清蛋白在牛奶中的含量仅为0.7%。从牛奶中分离出的乳清蛋白数量稀少,具有营养价值高、易消化吸收的特点。
低聚糖主要有2'-岩藻糖基乳糖和3'-半乳糖基乳糖,低聚糖的作用是提高免疫力,增强对感染的防御机制,维护肠道微生态平衡,以帮助逐渐建立起自己的免疫系统以及对大脑发育有促进帮助。
益生元:在奶粉中常见的益生元主要是低聚半乳糖、低聚果糖、多聚果糖等.益生元的作用是调节肠道健康。
乳铁蛋白是乳汁中一种重要的非血红素铁结合糖蛋白,主要由乳腺分泌.乳铁蛋白参与铁的转运,具有广谱抗菌、抗氧化、抗癌、调节免疫系统等功能,是一种新型抗菌、抗癌药物和极具开发潜力的食品和饲料添加剂。
乳脂球膜蛋白是乳腺在分泌时包被在脂肪外的膜蛋白,是磷脂、鞘磷脂(神经节苷脂、神经鞘磷脂、甘油磷脂)、多种蛋白组成的3层膜结构,只存在于人乳和动物乳汁中.乳脂球膜蛋白的作用:有助于脑部发育,减少中耳炎发病率,有益于认知与行为调节和调节肠道健康。
在上述实施例中,所述成人配方奶粉采用的乳粉为全脂乳粉;所述成人配方奶粉采用的复合微生物包括乳双歧杆菌HN019、动物双歧杆菌Bb-12和鼠李糖乳杆菌,所述复合微生物含量大于1×106CFU/100g。
在具体实施例中,复合微生物对机体的作用包括:
1)、抑制有害菌的繁殖,益生菌在人体内的繁殖利于维持肠道微生态的平衡,通过抢夺营养抑制有害菌的繁殖;
2)、是天然的抗生素,通过自身代谢可产生大量天然抗生素,杀死致病菌;
3)、利于营养素的合成,可以帮助人体完成自身无法完成的一些生化合成作用,例如硫胺素、核黄素、维生素B12、维生素A、维生素K等的合成;
4)、固氮的作用,可以预防蛋白质的不足;
5)、可以增加消化率和生物利用率,利于提高营养物质的吸收,例如有的宝宝是乳糖不耐受体质,益生菌可以可以分解乳糖为糖类和半乳糖,肠道就可以吸收了;所述糖类为低聚异麦芽糖、低聚果糖、低聚半乳糖、木糖醇或赤藓糖醇;
6)、减轻抗生素对身体的副作用,因抗生素的摄入引起的慢性肠炎,服用益生菌效果很好;
7)、预防和治疗便秘,可促进肠道蠕动减少大肠对水分的过度吸收,双歧杆菌最佳;
8)、提高免疫调节能力,可激活免疫细胞,增强免疫力,具有免疫调节能力。比如罗伊氏乳杆菌,鼠李糖乳杆菌可以预防宝宝过敏症状反复发生,改变过敏体质。
虽然以上描述了本发明的具体实施方式,但是本领域的技术人员应当理解,这些具体实施方式仅是举例说明,本领域的技术人员在不脱离本发明的原理和实质的情况下,可以对上述方法和系统的细节进行各种省略、替换和改变。例如,合并上述方法步骤,从而按照实质相同的方法执行实质相同的功能以实现实质相同的结果则属于本发明的范围。因此,本发明的范围仅由所附权利要求书限定。
Claims (9)
1.一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:包括以下配方:
基础营养元素,用于人体基础营养供能,所述基础营养元素包括蛋白质、脂肪和碳水化合物,所述蛋白质含量占原料成分的百分比为29%-35%,所述脂肪含量占原料成分的百分比为20%-23%,所述碳水化合物含量占原料成分的百分比为45%-48%,所述基础营养元素为人体基础营养总供能2002kJ/100g-2020kJ/100g;
矿物质元素,用于提高人体机能,所述矿物质元素包括钠、镁、铁、锌、锰、钙和硒,所述成人配方奶粉每100g中矿物质元素含量分别为钠300-330mg、镁40-46mg、铁6.0-7.9mg、锌5.5-6.5mg、锰230-240μg、钙850-1000mg和硒18.0-21.0μg,所述矿物质元素锌和铁通过参与人体酶合成实现机体免疫功能调节;
维生素元素,用于维持人体生理机能,所述维生素元素包括维生素A、维生素D、维生素E、维生素B6和维生素C,所述成人配方奶粉每100g中维生素元素含量分别为维生素A450-550μg、维生素D7.5-7.9μg、维生素E10.0-12.5mg、维生素B6500-1200μg和维生素C30-63mg,所述维生素A、维生素D和维生素B6调节通过增强细胞吞噬能力和杀伤能力调节机体免疫功能,所述维生素B6的添加量为600μg/100g,所述维生素C的添加量为40mg/100g;
强化营养成分,用于强化人体机能,所述强化营养成分包括二十二碳六烯酸DHA、二十碳四烯酸ARA、牛磺酸、核苷酸、胆碱和益生元,所述益生元包括低聚异麦芽糖和多聚果糖,所述强化营养成分占原料成分的百分比为二十二碳六烯酸0.20-0.25%、二十碳四烯酸0.3-0.5%、牛磺酸0.03-0.04%、核苷酸0.04-0.05%、胆碱0.01-0.15%、低聚半乳糖0.2-0.9%和多聚果糖3.6-4.2%,所述核苷酸和益生元通过改善肠道功能实现机体细胞免疫力增强;
强化免疫成分,用于重建及强化人体免疫功能,所述强化免疫成分包括表皮生长因子EGF、酵母β-葡聚糖和乳铁蛋白,表皮生长因子EGF含量占原料成分的百分比为0.008%-0.010%,酵母β-葡聚糖含量占原料成分的百分比为0.03%-0.10%,乳铁蛋白含量占原料成分的百分比为0.05%-0.08%,所述表皮生长因子通过修复呼吸道和消化道的上皮粘膜细胞防止细菌侵入,以提高人体机体免疫力。
2.根据权利要求1所述的一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:所述成人配方奶粉的制作过程包括以下步骤:
步骤一、采集新鲜生牛奶进行检验、过滤、净化和标准化处理,并将鲜奶与奶粉配方微量元素液体混合形成原料乳,所述原料乳中脂肪与无脂干物质的比例等于生产奶粉中脂肪与无脂干物质的比例;
步骤二、采用高温短时间或超高温瞬时杀菌方法对原料乳进行杀菌处理;
步骤三、加入蔗糖,所述成人配方奶粉的含糖量小于20%;
步骤四、通过真空浓缩去除原料乳中75%-80%的水分子,以提高奶粉的保藏性;
步骤五、通过高压或高速离心力实现原料乳喷雾干燥形成浓缩乳,所述浓缩乳通过雾化器向干燥室喷雾与热空气接触实现水分蒸发,以形成颗粒状奶粉。
3.根据权利要求1所述的一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:所述矿物质元素通过粒子群算法计算出锌和铁的最优摄入比例,以实现人体吸收最大化,所述矿物质元素锌和铁比例样本的集合为D,将所述集合D分为j个类别的集合为D=(D1,D2,...,Di,...,Dj),矿物质元素锌和铁比例样本类别Di需要经验熵的输出函数公式为:
在公式(1)中,pi为任意矿物质元素锌和铁的比例样本属于类别Di的概率,H(Di)为给定样本类别Di需要的经验熵;
不同矿物质元素锌和铁比例的免疫性能效果集合为A={a1,a2,...,av},采用免疫性能效果将矿物质元素锌和铁比例样本的集合D分为(D1,D2,...,DV),将A划分为子集的经验熵输出函数公式为:
在公式(2)中,E(A)为将A划分为子集的经验熵,Sij为子集Dj的免疫性能效果类别样本,s为矿物质元素锌和铁比例的样本数,H(Di)为给定样本类别Di需要的经验熵,E(A)值与免疫性能效果成反比。
4.根据权利要求1所述的一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:所述矿物质元素的化合物包括柠檬酸钠、硫酸镁、硫酸亚铁、硫酸锌、硫酸锰、碘化钾、碳酸钙和亚硒酸钠。
5.根据权利要求1所述的一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:所述维生素元素化合物包括脂溶性维生素化合物和水溶性维生素化合物。
6.根据权利要求1所述的一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:所述脂溶性维生素包括醋酸维生素A、维生素D、维生素E、dl-α-醋酸生育酚和植物甲萘醌;所述水溶性维生素包括维生素B6、维生素C、L-抗坏血酸、L-抗坏血酸钠、盐酸硫胺素、核黄素、盐酸吡哆醇、氰钴胺、D-泛酸钙和D-生物素。
7.根据权利要求1所述的一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:所述表皮因子EGF通过小分子多肽与应答细胞表面的受体结合实现受体二聚化和细胞质磷酸化,所述受体与不同序列的蛋白结合实现信号传导,以增强机体免疫功能。
8.根据权利要求1所述的一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:所述成人配方奶粉的组分重量份数包括植物脂肪粉25-35份、乳粉30-42.5份、乳清粉21.5-30份、糖类固体糖浆1.096-8.93份、乳清蛋白粉2-4份、低聚糖1.5-2.5份、复合维生素0.15-0.2份、复合矿物质0.35-0.6份、强化营养素1-1.5份和免疫营养素0.8-1.0份,所述糖类为低聚异麦芽糖、低聚果糖、低聚半乳糖、木糖醇或赤藓糖醇。
9.根据权利要求1所述的一种重建及强化人体免疫功能的成人配方奶粉,其特征在于:所述成人配方奶粉采用的乳粉为全脂乳粉;所述成人配方奶粉采用的复合微生物包括乳双歧杆菌HN019、动物双歧杆菌Bb-12和鼠李糖乳杆菌,所述复合微生物含量大于1×106CFU/100g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311233371.XA CN117121949A (zh) | 2023-09-22 | 2023-09-22 | 一种重建及强化人体免疫功能的成人配方奶粉 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311233371.XA CN117121949A (zh) | 2023-09-22 | 2023-09-22 | 一种重建及强化人体免疫功能的成人配方奶粉 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117121949A true CN117121949A (zh) | 2023-11-28 |
Family
ID=88852777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311233371.XA Pending CN117121949A (zh) | 2023-09-22 | 2023-09-22 | 一种重建及强化人体免疫功能的成人配方奶粉 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117121949A (zh) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105076418A (zh) * | 2015-08-17 | 2015-11-25 | 东北农业大学 | 一种促进婴儿大脑神经和胃肠组织发育的婴儿配方奶粉 |
CN108029768A (zh) * | 2017-11-29 | 2018-05-15 | 上海晨冠乳业有限公司 | 一种含乳铁蛋白和益生菌的婴幼儿配方奶粉及其制备方法 |
CN110097946A (zh) * | 2019-03-01 | 2019-08-06 | 西安电子科技大学 | 一种基于营养成分分析的饮食推荐方法 |
CN111184072A (zh) * | 2020-03-02 | 2020-05-22 | 上海育博营养食品有限公司 | 一种有利于增强免疫、提高抵抗力的奶粉及其生产方法 |
CN112471260A (zh) * | 2020-11-25 | 2021-03-12 | 中宁县黄河乳制品有限公司 | 一种提高人体免疫力的有机配方奶粉及其制备方法 |
CN112772723A (zh) * | 2021-01-07 | 2021-05-11 | 上海英贝康母婴用品有限公司 | 一种有利于儿童免疫系统发育的奶粉配方及其生产方法 |
CN113450882A (zh) * | 2020-09-27 | 2021-09-28 | 东莞太力生物工程有限公司 | 一种基于人工智能的基础培养基配方开发方法及系统 |
CN113935233A (zh) * | 2021-09-28 | 2022-01-14 | 暨南大学 | 一种饲料配方优化方法、系统、计算机及存储介质 |
CN114732051A (zh) * | 2022-03-10 | 2022-07-12 | 广州麦乐生物科技有限公司 | 一种重建及强化人体免疫功能的成人配方奶粉 |
CN115024364A (zh) * | 2022-06-23 | 2022-09-09 | 湖南茁睿生物科技有限公司 | 一种促进儿童成长骨骼发育的配方羊奶粉及其制备方法 |
US20230189865A1 (en) * | 2020-05-15 | 2023-06-22 | Enchanted Acres Farms, Inc. | Infant formula |
CN116434915A (zh) * | 2023-06-07 | 2023-07-14 | 北京四海汇智科技有限公司 | 保障儿童饮食营养均衡的管理方法及系统 |
-
2023
- 2023-09-22 CN CN202311233371.XA patent/CN117121949A/zh active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105076418A (zh) * | 2015-08-17 | 2015-11-25 | 东北农业大学 | 一种促进婴儿大脑神经和胃肠组织发育的婴儿配方奶粉 |
CN108029768A (zh) * | 2017-11-29 | 2018-05-15 | 上海晨冠乳业有限公司 | 一种含乳铁蛋白和益生菌的婴幼儿配方奶粉及其制备方法 |
CN110097946A (zh) * | 2019-03-01 | 2019-08-06 | 西安电子科技大学 | 一种基于营养成分分析的饮食推荐方法 |
CN111184072A (zh) * | 2020-03-02 | 2020-05-22 | 上海育博营养食品有限公司 | 一种有利于增强免疫、提高抵抗力的奶粉及其生产方法 |
US20230189865A1 (en) * | 2020-05-15 | 2023-06-22 | Enchanted Acres Farms, Inc. | Infant formula |
CN113450882A (zh) * | 2020-09-27 | 2021-09-28 | 东莞太力生物工程有限公司 | 一种基于人工智能的基础培养基配方开发方法及系统 |
CN112471260A (zh) * | 2020-11-25 | 2021-03-12 | 中宁县黄河乳制品有限公司 | 一种提高人体免疫力的有机配方奶粉及其制备方法 |
CN112772723A (zh) * | 2021-01-07 | 2021-05-11 | 上海英贝康母婴用品有限公司 | 一种有利于儿童免疫系统发育的奶粉配方及其生产方法 |
CN113935233A (zh) * | 2021-09-28 | 2022-01-14 | 暨南大学 | 一种饲料配方优化方法、系统、计算机及存储介质 |
CN114732051A (zh) * | 2022-03-10 | 2022-07-12 | 广州麦乐生物科技有限公司 | 一种重建及强化人体免疫功能的成人配方奶粉 |
CN115024364A (zh) * | 2022-06-23 | 2022-09-09 | 湖南茁睿生物科技有限公司 | 一种促进儿童成长骨骼发育的配方羊奶粉及其制备方法 |
CN116434915A (zh) * | 2023-06-07 | 2023-07-14 | 北京四海汇智科技有限公司 | 保障儿童饮食营养均衡的管理方法及系统 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6929793B2 (en) | Nutritional composition for treating an immune condition | |
RU2430631C2 (ru) | Пребиотическая смесь олигосахаридов и пищевой продукт, ее содержащий | |
RU2607457C2 (ru) | Молочная олигосахаридно-галактоолигосахаридная композиция для детской смеси, содержащая растворимую олигосахаридную фракцию, присутствующую в молоке, и имеющая низкое содержание моносахаридов, и способ получения композиции | |
US9757345B2 (en) | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes | |
CN110179121A (zh) | 一种改善肠道的五联益生菌组合物、复合固体饮料及其制备方法和应用 | |
MXPA99008953A (en) | Nutritional formulations containing oligosaccharides | |
AU2013251338B2 (en) | Fermented flavoring system derived from greek yogurt processing | |
JP2004065196A (ja) | 海水を利用したミネラル組成物 | |
CN109430382A (zh) | 一种具有调节血糖功效的配方食品及其制备方法 | |
CN112075504A (zh) | 增强免疫力的婴儿配方牛奶粉 | |
CN112167360A (zh) | 低致敏性的婴儿配方羊奶粉 | |
US20140322170A1 (en) | Fermented Flavoring System Derived from Greek Yogurt Processing | |
CN108669563A (zh) | 一种组合物、其应用和增强免疫力、改善过敏的产品 | |
CN117121949A (zh) | 一种重建及强化人体免疫功能的成人配方奶粉 | |
CN111642566A (zh) | 一种有利于儿童身高和智力发育的羊奶粉 | |
CN116114767A (zh) | 乳制品及其在制备抗炎产品中的应用 | |
CN114223728B (zh) | 含有益生元与益生菌的早产/低出生体重婴儿配方奶粉 | |
CN114431304A (zh) | 一种以驴乳为基料的二段婴儿配方乳粉及其制备方法 | |
Meena et al. | A comprehensive review on donkey milk and its products: composition, functionality and processing aspects | |
CN110810514A (zh) | 一种儿童奶粉及其制备方法 | |
CN115804410B (zh) | 含有可促进长双歧杆菌婴儿亚种ylgb-1496生长的益生元组合物的婴幼儿配方奶粉 | |
CN116548608B (zh) | 一种儿童全营养配方粉及其制备方法和应用 | |
DE19654614C2 (de) | Verfahren zur Herstellung von biologisch hochwertigen Sauermilcherzeugnissen | |
CN112385708A (zh) | 一种中老年富硒高钙羊奶粉及制备方法 | |
Shodiq et al. | The Quality of Yoghurt Fortification Tuna Fishbone (Thunnus sp.) Nanocalcium: Physicochemistry and Microstructure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |